|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry显示文摘瞄准:为颜色检测新浆液简历标记由浆液蛋白质与提高表面的激光解吸附作用 ionisation 介绍的表面的癌症(CRC )-- 飞行团分光术(SELDI-TOF MS ) 的时间。方法:二个独立浆液样品集合与 ProteinChip 技术独立被分析(集合 A:40 CRC+49 健康控制;集合 B:37 CRC+31 健康控制) ,有一个弱阳离子的使用的芯片交换一半和缓冲区 pH 5。差别的歧视的力量表示了蛋白质与一个分类树算法被估计。产生分类树的敏感和特性被盲目地从集合 B 并且反过来也如此从集合 A 把数据用于产生的树获得。CRC 浆液蛋白质侧面也与从胸的那些相比,卵巢,前列腺,和非小的房间肺癌症。结果:Mass-to-charge 比率(m/z ) 3.1x10 (3 ) , 3.3x10 (3 ) , 4.5x10 (3 ) , 6.6x10 (3 ) 和 28x10 (3 ) 在最好执行的分类树上被用作分类器。树敏感和特性在 65% 和 90% 之间。大多数这些歧视的 m/z 价值在调查的另外的瘤类型也是不同的。M/z 3.3x10 (3 ) ,在大多数树上的主要分类器,是 6.6x10 (3 ) 的一种二倍地控告的形式 -Da 蛋白质。后者作为 apolipoprotein C-I 被识别。M/z 3.1x10 (3 ) 作为 apolipoprotein A-I 作为白朊,和 m/z 28x10 (3 ) 的 N 终端碎片被识别。结论:分类树模式分析跟随的 SELDI-TOF MS 是为为 CRC 发现新浆液标记的一种合适的技术。Biomarkers 能与高敏感和特性在独立样品集合被识别并且 reproducibly 检测了。尽管为 CRC 不特定,这些简历标记在监视的疾病和治疗有一个潜在的角色。 | Judith YMN Engwegen Helgi H Helgason Annemieke Cats Nathan Harris Johannes MG Bonfrer Jan HM Schellens Jos H Beijnen | 2006 | World Journal of Gastroenterology2006，12，10： | 45 |
| 2 | Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies显示文摘 | Nicolas Widmer Christophe Bardin Etienne Chatelut Angelo Paci Jos Beijnen Dominique Levêque Gareth Veal Alain Astier | 2014 | European Journal of Cancer2014，，： | 2 |
| 3 | Cyclodextrins in the pharmaceutical field显示文摘 | Beker O Uijtendaal E V Beijnen J H | 1991 | Drug Dev Ind Pharm1991，17，11： | 1 |
| 4 | Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer显示文摘 | Kruijtzer CM Boot H Beijnen JH | 2003 | Ann Oncol2003，14，2： | 1 |
| 5 | Intravenous - to -oral switch in anticancer chemotherapy:a focus on do- eetaxel and paclitaxel 显示文摘 | Koolen S L Beijnen J H Schellens J H | 2010 | Clin Pharmacol Ther2010，87，1： | 1 |
| 6 | Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers显示文摘 | M. Joerger T. M. Bosch V. D. Doodeman J. H. Beijnen P. H. M. Smits J. H. M. Schellens | 2006 | European Journal of Clinical Pharmacology2006，，8： | 1 |
| 7 | Proteomics in uveal melanoma显示文摘 | Missotten G S Beijnen J H Keunen J E | 2003 | Melanoma Res2003，13，6： | 1 |
| 8 | Rapid esterasesensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokineties of docetaxel and metabolites in mice 显示文摘 | van Tellingen O Beijnen JH Verweij J | 1999 | Clin Cancer Res1999，5，10： | 1 |
| 9 | Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice 显示文摘 | Van Tellingen O Beijnen JH Verweij J | 1999 | Clin Cancer Res1999，5，10： | 1 |
| 10 | Development of famesyl transferase inhibitors: a review显示文摘 | Appels N M Beijnen J H SchelIens J H | 2005 | Oncologist2005，10，8： | 1 |
| 11 | Concise review;Clinicalrelevance of drug drug and herb drug interactions mediated by the ABCtransporter ABCB1 ( MDR1,P-glycoprotein) 显示文摘 | Marchetti S Mazzanti R Beijnen JH ef al | 2007 | Oncologist2007，12，8： | 1 |
| 12 | Inhibitors of roTOR显示文摘 | Klumpen HJ Beijnen JH Gurney H | 2010 | Oncologist2010，15，12： | 1 |
| 13 | Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours显示文摘 | VINK S R SCHELLENS J H BEIJNEN J H | 2006 | Radiother Oncol2006，80，2： | 1 |
| 14 | Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives 显示文摘 | Van Tellingen O Sips JHM Beijnen JH | 1992 | Anticancer Res1992，12，： | 1 |
| 15 | Clinical experience with aurora kinaseinhibitors:Areview显示文摘 | BOSS D S BEIJNEN J H SCHELLENS J H M | | Oncologist0，14，8： | 1 |
| 16 | Incidence and risk factors for nevirapine-associated rash显示文摘 | Monique M. R. Maat Rob Heine Jan W. Mulder Pieter L. Meenhorst Albert T. A. Mairuhu Eric C. M. Gorp Alwin D. R. Huitema Jos H. Beijnen | 2003 | European Journal of Clinical Pharmacology (-)2003，，5： | 1 |
| 17 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer显示文摘 | Bosch T M Meijerman I Beijnen J H Schellens J H | 2006 | Clin Pharmacokinet2006，45，3： | 1 |
| 18 | Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines显示文摘 | P.J.M. van de Vaart N. van der Vange F.A.N Zoetmulder A.R. van Goethem O. van Tellingen W.W. ten Bokkel Huinink J.H. Beijnen H. Bartelink A.C. Begg | 1997 | European Journal of Cancer1997，，1： | 1 |
| 19 | Validation of previously identified serum biomarkers for breast cancer with SELDITOF MS:a case control study显示文摘 | van Winden AW Gast MC Beijnen JH | | 0，，： | 1 |
| 20 | Coadministration of cyclosporine strongly enhances the oral bioavailability of do- cetaxel显示文摘 | Malingr MM Richel DJ Beijnen JH | 2001 | J Clin Oncol2001，19，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员